Australia markets closed

    -27.70 (-0.35%)
  • ASX 200

    -25.40 (-0.33%)

    -0.0029 (-0.43%)
  • OIL

    +0.18 (+0.23%)
  • GOLD

    +30.80 (+1.33%)
  • Bitcoin AUD

    -970.05 (-0.95%)
  • CMC Crypto 200

    +8.81 (+0.62%)

    +0.0010 (+0.17%)

    +0.0026 (+0.24%)
  • NZX 50

    -7.75 (-0.07%)

    +111.74 (+0.57%)
  • FTSE

    -16.93 (-0.21%)
  • Dow Jones

    -65.11 (-0.17%)
  • DAX

    -250.14 (-1.37%)
  • Hang Seng

    -170.85 (-0.94%)
  • NIKKEI 225

    +94.09 (+0.24%)

Macrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ...

  • Revenue: Reported at $9.1 million for Q1 2024, a significant decrease from $24.5 million in Q1 2023, falling short of estimates of $14.62 million.

  • Net Loss: Increased to $52.2 million in Q1 2024 from $38.0 million in Q1 2023, more than the estimated net loss of $40.89 million.

  • R&D Expenses: Remained stable at $46.0 million in Q1 2024 compared to $45.9 million in Q1 2023.

  • SG&A Expenses: Rose to $14.7 million in Q1 2024 from $13.5 million in Q1 2023, primarily due to increased stock-based compensation and professional fees.

  • Cash Position: Cash, cash equivalents, and marketable securities totaled $184.2 million as of March 31, 2024, down from $229.8 million at the end of 2023.

  • Cash Runway Guidance: Current financial resources are expected to fund operations into 2026, reflecting ongoing clinical and preclinical study expenditures.

  • Earnings Per Share: Recorded a loss of $0.84 per share in Q1 2024, which was more than the estimated loss per share of $0.64.

On May 9, 2024, Macrogenics Inc (NASDAQ:MGNX) released its first-quarter financial results and provided updates on its clinical trials and product development via an 8-K filing. The biopharmaceutical company, known for its innovative antibody-based therapeutics for cancer treatment, reported a net loss and a decrease in revenue compared to the previous year, alongside promising clinical updates.

Company Overview

Macrogenics Inc focuses on the discovery, development, and commercialization of monoclonal antibody-based therapeutics for the treatment of cancer. Its product portfolio includes MARGENZA for metastatic HER2-positive breast cancer and several other candidates targeting tumor-associated antigens and immune checkpoints.

Financial Performance

The first quarter of 2024 saw Macrogenics generate revenue of $9.1 million, a significant drop from the $24.5 million recorded in the same quarter the previous year. This decrease was largely due to reduced revenue from collaborative and other agreements, notably missing a $15.0 million milestone payment received in Q1 2023 from Incyte. Research and development expenses remained stable at $46.0 million, reflecting ongoing investment in their extensive clinical pipeline.


Macrogenics reported a net loss of $52.2 million for the quarter, deepening from a net loss of $38.0 million in Q1 2023. The increased loss can be attributed to the lower revenue and slightly increased selling, general, and administrative expenses, which rose to $14.7 million due to higher stock-based compensation and professional fees.

Clinical Development Highlights

Significant clinical progress was reported, particularly with the TAMARACK Phase 2 study of vobra duo in metastatic castration-resistant prostate cancer (mCRPC). Promising interim safety and efficacy data support the potential of vobra duo, with plans to initiate a Phase 3 study in 2025. The study showed notable disease control and overall response rates, indicating the drug's potential effectiveness.

Additionally, Macrogenics is expanding the TAMARACK study to include other cancers and continues to advance its pipeline with multiple other candidates in various stages of development.

Financial Health and Outlook

The company's cash position as of March 31, 2024, was $184.2 million, down from $229.8 million at the end of 2023. Despite the decrease, Macrogenics expects its current funds, alongside projected future payments from partners and product revenues, to sustain its operations into 2026. This projection underscores the company's strategic planning in balancing clinical advancement with financial sustainability.


While the financial results for Q1 2024 fell short of some expectations, particularly in revenue generation, Macrogenics' consistent R&D investment and robust clinical pipeline are critical for its long-term strategy. The ongoing clinical trials and upcoming data readouts will be pivotal in determining the company's future trajectory and potential market impact. Investors and stakeholders will likely keep a close watch on the progression of key trials like TAMARACK and the expansion into new cancer studies.

For more detailed information on Macrogenics Inc's financials and clinical developments, please refer to their official 8-K filing.

Explore the complete 8-K earnings release (here) from Macrogenics Inc for further details.

This article first appeared on GuruFocus.